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Versican splice variant messenger RNA expression in
normal human Achilles tendon and tendinopathies
A. N. Corps, A. H. N. Robinson1, T. Movin2, M. L. Costa1, D. C. Ireland3,
B. L. Hazleman and G. P. Riley
Objectives. Versican is the principal large proteoglycan expressed in mid-tendon, but its role in tendon pathology is unknown.
Our objective was to deﬁne the expression of versican isoform splice variant messenger ribonucleic acid (mRNA) in normal
Achilles tendons, in chronic painful tendinopathy and in ruptured tendons.
Methods. Total RNA isolated from frozen tendon samples (normal n¼ 14; chronic painful tendinopathy n¼ 10; ruptured n¼ 8)
was assayed by relative quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for total versican, versican
variants V0, V1, V2, V3 and type I collagen 1 mRNA, normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Differences between sample groups were tested by Wilcoxon statistics.
Results. Painful and ruptured tendons showed a signiﬁcant decrease (median 2-fold) in the expression of versican mRNA, in
contrast to an increased expression (median 8-fold) of type I collagen 1 mRNA in painful tendons. Versican splice variants V0
and V1 mRNA were readily detected in normal samples, V3 levels were substantially lower, and V2 levels were more variable.
Each of V1, V2 and V3 mRNA showed signiﬁcant decreases in expression in painful and ruptured tendons, but V0 was not
signiﬁcantly changed.
Conclusions. Changes in versican expression relative to that of collagen, and alterations in the balance of versican splice
variants, may contribute to changes in matrix structure and function in tendinopathies.
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The large extracellular matrix proteoglycan versican contributes to
the structural properties of the matrix through its ability to bind
hyaluronic acid and the glycosaminoglycan (GAG) chondroitin
sulphate, and also modulates cell growth, migration and differ-
entiation [1]. There are four versican isoforms, which contain
different combinations of two GAG-binding domains, termed
GAG and GAG, due to differential splicing of exons 7 and 8: V0
has both of these domains, V1 has GAG only, V2 has GAG only
and V3 has neither [2, 3]. The wide range of interactions mediated
by versican is thought to result from differential expression of
the GAG domains and from properties conferred by the N- and
C-terminal domains [1].
In tendons, studies of both protein and messenger ribonucleic
acid (mRNA) localization have indicated that there is site-speciﬁc
distribution of the large proteoglycans: versican is predominant in
the tensile region of the mid-tendon, while aggrecan is more highly
expressed in the ﬁbrocartilagenous regions at the insertion sites or
where the tendon wraps around bone [4, 5]. Versican forms an
integral part of a pericellular matrix that organizes the tendon cells
in linear arrays between collagen fascicles [6]. The splice variants of
versican that are expressed in human tendons such as the Achilles
have not been described. These tendons are commonly subject to
chronic painful degeneration or ‘tendinosis’ [7, 8], and to rupture,
which is often spontaneous, i.e. previously asymptomatic,
although underlying histochemical changes are frequently present
[9, 10]. Most tendon damage occurs in the mid-tendon region, with
structural and biochemical changes including increased levels of
GAG [7–10]. Whether versican is involved in these tendinopathies
is not known. We have developed relative quantitative reverse
transcriptase polymerase chain reaction (RT-PCR) assays for total
versican and the different splice variants, and we have addressed
two questions: which versican splice variant mRNAs are expressed
in Achilles tendon and how does versican mRNA expression
change in tendinopathies?
Materials and methods
Materials
Oligonucleotide primers for RT-RCR were obtained from
Invitrogen (Paisley, UK). One-Step RT-PCR reagents and ﬂuores-
cein (FAM)-labelled oligonucleotide probes were obtained from
Applied Biosystems (Warrington, UK).
RNA isolation from tendon specimens
All procedures were approved by the Cambridge Local Research
Ethics Committee and written consent was obtained from
informed patients. Tendon specimens were obtained from tissue
discarded during surgery, from 10 patients suffering painful
tendinopathy for more than 6 months, and from eight patients
undergoing repair of ruptured tendon within 48 h of the rupture
occurring. Macroscopically normal specimens were obtained from
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cadaver material (14 individuals) within 48 h of death. The age of
the individuals from which tissue was taken was as follows: normal
tendon, 20–97 yr (mean¼ 58 yr; median¼ 54 yr); painful tendino-
pathy, 32–58 yr (mean¼ 44 yr; median¼ 44 yr); ruptured tendon,
33–69 yr (mean¼ 47 yr; median¼ 44 yr). Pieces of mid-tendon
(between 10 and 70mg wet weight) were frozen at 70C.
RNA was isolated from the frozen tissue samples by a modiﬁed
Tri-Spin protocol as described previously [11], resuspended in
100l water, and quantitated using the RiboGreen assay
(Molecular Probes, Leiden, The Netherlands). The majority of
samples yielded between 20 and 70 ng RNA/mg wet weight,
consistent with our previous experience of human tendon samples
of low cellularity [11]. The RNA was diluted to 1 ng/l, and stored
at 70C as aliquots which were thawed once only.
Relative quantitative RT-PCR
One-Step RT-PCR reactions were performed in a GeneAmp 5700
(Applied Biosystems, Warrington, UK). Primers and probes
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
type I collagen 1-chain (collI1) have been described previously
[11]. Primers and probes for versican mRNA were designed using
Primer Express (Applied Biosystems). BLASTn searches
(www.ncbi.nlm.nih.gov/BLAST) revealed no signiﬁcant similarity
to other sequences. The forward primer (F), reverse primer (R) and
probe (P) sequences were as follows:
Total versican (accession number U16306: bp 161–277):
F¼CCACCACGCTTCCTATGTGA
R¼TTTATGAACATCTTGGCCTTGGA
P¼CGCCGAACCCAGTCGCGC
Versican V0 (accession number U16306: bp 4210–4314):
F¼GCACAAAATTTCACCCTGACAT
R¼CTGAATCTATTGGATGACCAATTACAC
P¼ATCACTCATTCGACCTGTCTTATTTTCTCTGACC
Versican V1 (accession number X15998: bp 1231–1353):
F¼TGAGAACCCTGTATCGTTTTGAGA
R¼ as V0
P¼AATCACTCATTCGACGTTTAAAGCAGTAGGCA
Versican V2 (accession number U26555: bp 4210–4305):
F¼ as V0
R¼CGTTAAGGCACGGGTTCATT
P¼TCAGAGAAAATAAGACAGGACCTGATCGCTGC
Versican V3 (accession number D32039: bp 1070–1183):
F¼ as V1
R¼ as V2
P¼CAGATTTGATGCCTACTGCTTTAAACGACCTG
All probes were chosen to span exon splice junctions. The
amplicon for total versican mRNA spans the splice junction
between exons 3 and 4, which are present in all variants [3]. The
variant-speciﬁc amplicons span the variably deleted exons 7 and 8
(Fig. 1), the sizes of which (2961 bp and 5262 bp) prevent
ampliﬁcation of the wrong products from shared primer sequences,
and each primer pair generated a single product of the appropriate
size. No signal was produced if either the RNA or the reverse
transcriptase was omitted. To conﬁrm that each of the assays was
not affected by the presence of the shared sequences within the
other variants, we prepared and used longer PCR products from
the V0 and V1 variants. Each of these acted as a template in the
assay of the respective variant, but did not interfere or generate
signals in assays of each of the other variants (data not shown).
Standard curves were run in each assay, using freshly-diluted
aliquots of pooled tendon tissue or cell RNA, or of brain RNA for
versican V2. For each target, this produced a linear plot of
threshold cycle (Ct) against log(dilution), whose slope was within
10% of the expected value, indicating a similar, near-maximum
efﬁciency for each target. All tissue RNA samples were assayed in
duplicate on the same plate at 2 ng/well, and each target assay was
performed at least twice with similar results. The values obtained
for versican mRNA expression were normalized for GAPDH
mRNA expression in the same sample, using the formula
versican=GAPDH ¼ 2½CtðGAPDHÞCtðversicanÞ:
The expression of GAPDH mRNA showed some heterogeneity
between tissue samples, particularly in the group from ruptured
tendons. However, there was no overall signiﬁcant difference in
GAPDH expression between the three tissue sample groups.
Analysis of data
Comparison of the expression levels of each versican mRNA
between tissue sample groups was performed using the Wilcoxon
rank sum test.
Results
Using an assay which detects all reported splice variants of
versican, we found that the total versican mRNA expression in
tendon samples was generally in the range 0.1–1 compared with
that of GAPDH, i.e. moderately high levels. Compared with the
expression in normal tendons, both painful and ruptured tendons
showed a signiﬁcant decrease (median 2-fold) in the expression of
versican mRNA (Fig. 2A). In contrast, the expression of collI1
mRNA showed a marked (median 8-fold) increase in samples of
painful tendon but was more variable in samples of ruptured
tendon (Fig. 2B).
Using assays speciﬁc for versican splice variant mRNA, we
found that all four variants were expressed in most samples
(Fig. 2). The similar optimized efﬁciencies of the different assays
allowed approximate comparisons between the different variants.
In normal tendon samples, V0 and V1 mRNA were consistently
expressed at similar levels (estimates of the median V0/V1 ratio
were 1.0, 1.4 and 1.8 in three separate pairs of assays), and were
generally about 10-fold higher than V3 mRNA. Variant V2
mRNA showed the most variable expression, ranging from similar
to that of V0 and V1 mRNA in some samples to less than that of
V3 mRNA in other samples. In painful and ruptured tendon
samples, V1 mRNA showed reduced expression compared with
normal samples (median 2-fold), i.e. similar to that observed in
total versican mRNA (Figs 2A,D). V2 and V3 mRNA showed
proportionally greater reductions, the levels being near or below
the detection limit in some samples (Figs 2E, F). In contrast, the
expression of V0 mRNA in painful or ruptured tendon samples
was not signiﬁcantly different from that in normal tendon
samples (Fig. 2C). In painful tendon samples the ratio of V0/V1
or V0/(total versican) was doubled compared with normals
(P<0.05), but in ruptured tendon samples these ratios showed
greater variation and no signiﬁcant difference.
Discussion
Versican expression has been detected in many adult human tissues
[12, 13]. The expression of the different splice variant mRNA varies
considerably, indicating complex levels of regulation, and only
three out of 21 tissues screened expressed all four variants at levels
considered signiﬁcant [13]. Variant V2 predominated in brain [14],
but was not detected in vascular smooth muscle cells [15]. Variant
V1 was the predominant form expressed in many tissues [13],
including cartilage, in which V0 and V3 were additionally
expressed only in the fetus [16]. We have shown here that versican
mRNA is expressed in normal and degenerate mid-tendon.
Although V0 and V1 mRNA were generally expressed at readily
detectable levels, both total versican mRNA and the individual
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splice variants showed rather large variation within the sample
groups, particularly the normal group, in which the proportion of
V2 mRNA was most variable. We do not know the basis for this
variation. However, since tendon is generally of low cellularity,
some of the variation may result from the inclusion of different
cell types, perhaps reﬂecting vascularization or innervation.
Alternatively, some of the normal samples may be affected by
subclinical degeneration: histopathological changes were reported
in 34% of normal (i.e. asymptomatic) tendons [9]. In cell culture
studies, we have found that ﬁbroblasts derived from tendon
explants express variant V0 and V1 mRNA at substantially higher
levels than variant V3, while V2 expression is low or undetectable
(ANC, unpublished data). We will use this model to investigate the
regulation of versican expression in tendon.
In samples from painful and ruptured tendons there was
decreased expression of versican mRNA. In earlier work, we
reported an increase in versican mRNA in three out of four
degenerate Achilles tendon samples (two painful and two
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FIG. 2. Expression of versican and collI1 mRNA in normal, painful and ruptured tendons: (A) total versican mRNA, (B) collI1
mRNA and (C–F) versican splice variant V0, V1, V2 and V3 mRNA were assayed and normalized for GAPDH mRNA. Each point
represents a separate sample, and the median values are indicated. *P<0.05, **P<0.01, ***P<0.001 compared with the normal
sample group.
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FIG. 1. Versican exon structure showing location of primers for total and variant-speciﬁc RT-PCR.
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ruptured) compared with the normal control, analysed on a
complementary deoxyribonucleic acid (cDNA) array [11]. The
contrast between the two studies may have arisen from the small
number of samples screened in the earlier work, with the normal
control being equivalent (in versican mRNA content) to the lower
end of the range described here. In the present study, the decrease
in versican mRNA in painful tendon samples was observed for
each variant except V0, so that the proportion of V0 relative to
the other variants doubled. An opposite result was obtained in
abdominal aortic aneurysm, where the expression of V0 mRNA
decreased but that of V1 remained constant [17], again indicating
situation-speciﬁc regulation of the splice variants. The decrease in
versican mRNA contrasted with a substantially increased expres-
sion of collI1 mRNA in the painful tendon samples. Versican
and collagen expression also show reciprocal regulation in the
cervix during pregnancy and involution, presumably reﬂecting a
physiological change in matrix structure and function [18].
The contribution of decreased versican mRNA expression and
an altered balance of versican splice variants to the structural and
functional changes in tendinopathies remains to be established. It
will be important to determine whether the changes in versican
mRNA expression are translated into changes at the protein level.
Among the biochemical changes occurring in tendinopathies
are increased levels of GAG [7–10], but it is not known which
proteoglycans are involved. A similar increase in GAG (median
3.5-fold) occurred in the samples of painful tendon used in this
study (VA Curry and GPR, unpublished data), despite the
signiﬁcantly decreased level of versican mRNA. The increase in
GAG in tendinopathies may therefore result from increased
expression of other proteoglycans (such as decorin, biglycan,
ﬁbromodulin or syndecans), although increased saturation of
GAG-binding sites in versican and decreased turnover of proteo-
glycan cannot be excluded. We are currently adapting methods of
proteoglycan identiﬁcation and analysis to the small samples of
human tendon available, in order to address this question.
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Key messages
 In mid-tendon, the principal versican
mRNA splice variants encode V0 and
V1.
 Decreased versican mRNA expression
may contribute to altered matrix struc-
ture and function in chronic tendino-
pathy and ruptured tendon.
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